Citi upgraded Silk Road Medical to Buy from Neutral with an unchanged price target of $50. The shares have traded down 26% year-to-date as the Q4 report fell short of "lofty" expectations and reimbursement questions arose, the analyst tells investors in a research note. The firm cites the pullback in the shares for the upgrade. The company’s 2023 will focus on moving existing trained physicians "up the adoption curve," says Citi.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical upgraded to Buy from Neutral at Citi
- Silk Road Medical initiated with a Buy at B. Riley
- Silk Road Medical upgraded to Neutral from Sell at Citi
- Silk Road Medical reports Q4 EPS (34c), consensus (38c)
- Silk Road Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Outlook
